Lacking the ability to pay for pricey hepatitis C treatments, the Louisiana Department of Health is exploring a pair of controversial options. One is reaching a deal with drug makers, such as Gilead Sciences, to license production to a generic company, while the other would be to ask the federal government to override patents so cheaper versions can be made by other manufacturers.

The state agency is responsible for covering approximately 35,000 Medicaid beneficiaries and uninsured residents, but covering the cost of hepatitis C treatments at current prices would run an estimated $764 million. In the current year, the Medicaid pharmacy program expects to spend just $76.2 million, according to a department spokesman.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Would that be COMPULSORY LICENSE? That would be funny if US Trade Representative would list State of Louisiana as a ROUGE state and in violation of trade practices US negotiated with World Trade Organization.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy